Lotus, NRx and Alvogen team up for S-TRBD therapy NRX-101

2023-06-06

细胞疗法引进/卖出

Lotus, NRx and Alvogen team up for S-TRBD therapy NRX-101

Preview

来源: Pharmaceutical Technology

NRX-101 will be used for suicidal treatment-resistant bipolar depression. Credit: Lotus.

Lotus Pharmaceuticals, NRx Pharmaceuticals and Alvogen have entered a global collaboration deal to develop and commercialise NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD).

Lotus will purchase global rights for NRX-101 and handle the commercialisation activities of the product in markets outside the US.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - CYMS-101 in Relapsing Remitting Multiple Sclerosis (RRMS) GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Gene-Modified Cell Therapy for Hypophosphatasia GlobalData

View allCompanies IntelligenceLotus Pharmaceuticals IncNRX Pharmaceuticals IncAlvogen IncView all

The company will collaborate with Alvogen Alvogen to commercialise NRX-101 in the US through the Almatica label, the CNS-focused division of Alvogen Alvogen.

Lotus and Alvogen will also provide funding for the next registrational trial to support NRX-101’s approval.

They will have a right to negotiate for new indications for NRX-101 outside the field of suicidal bipolar depression and/or potential new products comprising D-cycloserine along with an antidepressant/antipsychotic.

NRx Pharmaceuticals will receive an initial payment of $10m on obtaining successful findings from the ongoing Phase IIb/III clinical trial and on completion of a Type B meeting with the US Food and Drug Administration (FDA).

The company will receive a further $5m on gaining US FDA approval for NRX-101, and $330m milestone payments on reaching net sales targets.

It will also be eligible for a royalty on net sales between 12% and 16%, contingent upon meeting sales thresholds in the US market, and for payments based on the success of the product in other global markets.

NRx Pharmaceuticals CEO Stephan Willard stated: “This collaboration can accelerate the delivery of NRX-101 to patients grappling with suicidal bipolar depression who desperately need better treatment alternatives.

“This global partnership significantly minimises the need for future capital raises for NRX-101 development and commercialisation.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构